APSR2026-830

 
Late-Breaking
Submitted
Oral Presentation
AO27-005
 
 
https://storage.unitedwebnetwork.com/files/1285/1221246-46903-APSR-830.pptx_440901.pptx
Format: PPTX Only
 
Format: PDF Only
06. Tuberculosis
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Andy Sulaiman Siregar * Faculty Medicine of Universitas Sumatera Utara Magister Students of Biomedical Science Program Medan Indonesia
Mutiara Indah Sari - - Faculty Medicine of Universitas Sumatera Utara Department of Biochemistry Medan Indonesia
Dedi Ardinata - - Faculty Medicine of Universitas Sumatera Utara Departement of Physiology Medan Indonesia
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Andy Sulaiman
Siregar
andyslmn@gmail.com
+6281370317687
41-50
Indonesia
Trial in Progress (TiP) Abstract
Effect of a single session of wet cupping therapy combined with intensive phase anti-tuberculosis treatment on serum IL-6 and IFN-γ levels in pulmonary tuberculosis patients
Maximum 25 words
Abstract Content
 
 
 
 
 
 
 
Background : Pulmonary tuberculosis (TB) remains a major global health burden, particularly in developing countries. Although anti-tuberculosis drug treatment (ATD) effectively eliminates Mycobacterium tuberculosis, persistent inflammation and immune dysregulation contribute to pulmonary tissue damage and adverse clinical outcomes. Interferon-gamma (IFN-γ) plays a key role in macrophage activation and cellular immune responses, while interleukin-6 (IL-6) reflects systemic inflammatory activity and disease severity. Wet cupping therapy, as a complementary intervention, has been reported to exert immunomodulatory effects. However, controlled clinical evidence evaluating its impact on cytokine profiles in pulmonary TB patients remains limited.
Methods : This study is designed as a non-randomized controlled trial with a pretest–posttest approach. Newly diagnosed pulmonary tuberculosis patients undergoing intensive-phase anti-tuberculosis drug (ATD) treatment will be allocated into two groups: a control group receiving ATD alone and an intervention group receiving ATD combined with a single session of wet cupping therapy, administered according to standardized procedures at the beginning of the intensive phase. The primary outcomes are changes in serum interleukin-6 (IL-6) and interferon-gamma (IFN-γ) levels before and after intervention. Statistical analysis will be performed to evaluate within-group changes and between-group differences using appropriate parametric or non-parametric tests based on data distribution, with sample size estimation ensuring adequate statistical power. Inclusion criteria include newly diagnosed pulmonary TB patients eligible for intensive-phase ATD, while patients with severe comorbidities, immunocompromised conditions, or contraindications to cupping therapy will be excluded. Clinical Trial Registration: Submitted to Clinical Trials Registry of India (CTRI); registration under review (Acknowledgement No.: REF/2026/02/123629).
No
No
 
JPG or JPEG or PNG format ONLY
Pulmonary tuberculosis, Cytokines, Wet cupping therapy
maximum 3 keywords and no abbreviations, separated by commas
The authors declare no conflict of interest.
249